Trials Sponsors Conditions Drugs Pricing

Conditions

Gastrointestinal Carcinoid Tumor Islet Cell Carcinoma

Keywords

localized gastrointestinal carcinoid tumormetastatic gastrointestinal carcinoid tumorrecurrent gastrointestinal carcinoid tumorregional gastrointestinal carcinoid tumorrecurrent islet cell carcinomagastrinomainsulinomaWDHA syndromeglucagonomapancreatic polypeptide tumorsomatostatinoma

Interventions

octreotide acetateDrug

vatalanibDrug

somatostatin analogue therapyProcedure

Eligibility Criteria

Age18 Years - 120 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed low-grade neuroendocrine tumors * The following tumor types are excluded: * Small cell lung cancer * Medullary thyroid cancer * Paraganglioma * Pheochromocytoma * Measurable disease * Radiographic evidence of disease progression after completion of any prior systemic therapy, chemoembolization, bland embolization, or observation within the past year, defined as either of the following: * Appearance of a new lesion * At least 20% increase in the longest diameter (LD) of any previously documented lesion or an increase in the sum of the LDs of multiple lesions in the aggregate of 20% PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 75,000/mm\^3 * Hemoglobin ≥ 8.0 g/dL Hepatic * Bilirubin ≤ 2.0 times upper limit of normal (ULN) * AST ≤ 3 times ULN (5 times ULN if liver metastases are present) Renal * Creatinine ≤ 1.5 times ULN * Meets 1 of the following criteria: * Urine protein negative by dipstick * Urine protein:creatinine ratio \< 1.0 * Urine protein \< 1 g by 24-hour urine collection Gastrointestinal * Must be able to swallow tablets * No ulcerative disease * No uncontrolled nausea, vomiting, or diarrhea * No bowel obstruction * No other gastrointestinal tract disease resulting in an inability to take oral medication Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Must be able to receive a contrast-enhanced CT scan * No known history of allergic reaction to vatalanib or its derivatives or octreotide injections PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * At least 4 weeks since prior chemotherapy * No more than 1 prior systemic chemotherapy regimen * Chemoembolization is not considered systemic chemotherapy * No concurrent chemotherapy Endocrine therapy * Not specified Radiotherapy * At least 3 weeks since prior radiotherapy * No concurrent radiotherapy Surgery * At least 4 weeks since prior major surgery Other * At least 4 weeks since other prior systemic therapy * At least 4 weeks since prior local liver therapy * No prior anti-vascular endothelial growth factor agents * No concurrent grapefruit or grapefruit juice * No concurrent therapeutic warfarin or similar oral anticoagulants that are metabolized by the cytochrome P450 system * Concurrent heparin allowed

Sponsors & Collaborators

Eastern Cooperative Oncology Group
Research networklead
National Cancer Institute (NCI)
NIHcollaborator

MeSH Terms

Conditions

Carcinoma, Islet CellGastrinomaInsulinomaVipomaGlucagonomaSomatostatinoma

Interventions

OctreotidevatalanibBiological Therapy

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsPancreatic Neoplasms

Study Officials

Kyle Holen, MD
University of Wisconsin, Madison
STUDY CHAIR
Mary Mulcahy, MD
Robert H. Lurie Cancer Center

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Purpose: TREATMENT
Sponsor Type: NETWORK

Study Record Dates

First Submitted

September 26, 2005

First Posted

September 28, 2005

Last Updated

October 8, 2015

Record last verified: 2015-10

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00227773
Data provider: ClinicalTrials.gov
Source updated: 2015-10-08
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:23:28 UTC

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Intervention Hierarchy (Ancestors)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Intervention Hierarchy (Ancestors)